Ultragenyx Pharmaceutical Inc.
RARE
$35.11
-$0.87-2.42%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 139.29M | 164.88M | 139.49M | 147.03M | 108.83M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 139.29M | 164.88M | 139.49M | 147.03M | 108.83M |
| Cost of Revenue | 194.43M | 714.76M | 21.02M | 182.78M | 196.02M |
| Gross Profit | -55.14M | -549.88M | 118.47M | -35.76M | -87.19M |
| SG&A Expenses | 87.80M | 82.50M | 80.35M | 80.60M | 78.16M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 282.23M | 287.16M | 271.48M | 263.39M | 274.18M |
| Operating Income | -142.94M | -122.28M | -131.99M | -116.36M | -165.35M |
| Income Before Tax | -149.77M | -133.40M | -133.21M | -130.74M | -170.23M |
| Income Tax Expenses | 1.31M | -19.00K | 303.00K | 858.00K | 455.00K |
| Earnings from Continuing Operations | -151.08M | -133.39M | -133.52M | -131.60M | -170.68M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -151.08M | -133.39M | -133.52M | -131.60M | -170.68M |
| EBIT | -142.94M | -122.28M | -131.99M | -116.36M | -165.35M |
| EBITDA | -133.95M | -113.20M | -123.23M | -107.50M | -156.50M |
| EPS Basic | -1.57 | -1.39 | -1.40 | -1.52 | -2.03 |
| Normalized Basic EPS | -0.97 | -0.86 | -0.88 | -0.92 | -1.29 |
| EPS Diluted | -1.57 | -1.39 | -1.40 | -1.52 | -2.03 |
| Normalized Diluted EPS | -0.97 | -0.86 | -0.88 | -0.92 | -1.29 |
| Average Basic Shares Outstanding | 96.29M | 95.68M | 95.49M | 86.58M | 84.29M |
| Average Diluted Shares Outstanding | 96.29M | 95.68M | 95.49M | 86.58M | 84.29M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |